<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"><!--CONVEX # converter_version:9.16.1 # generated_on:20250113-1145--><head><!--genuine root filename=IMMC.COM%282025%296%20final.ENG.xhtml.1_EN_ACT_part1_v2:normalized root filename=IMMC.COM%282025%296%20final.ENG.xhtml.1_EN_ACT_part1_v2:COMtype from docvar=COM:year from docvar=2025:number from docvar=0006:final from docvar=FIN:langue from docvar=ENG:LW_REF_INST_NEW=COM:LW_REF_INST_NEW_ADOPTED=final:LW_REF_INST_NEW_TEXT=(2025) 6:LW_LANGUE=EN--><!--cellarImageNamePrefix="COM_2025_0006_FIN.ENG.xhtml"--><!--poorGenuineFilename="COM_2025_0006_FIN_ENG"--><title>IMMC.COM%282025%296%20final.ENG.xhtml.1_EN_ACT_part1_v2.docx</title>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
      <link type="text/css" rel="stylesheet" href="http://publications.europa.eu/resource/presentation-style-sheet/com/com-c.css"/>
   </head>
   <body>
      <div class="contentWrapper">
         <div class="content"><!--all docVars name and value:(35),[name=CR_RefLast;value="0"],[name=DQCDateTime;value="2025-01-13 08:30:10"],[name=DQCResult_Distribution;value="0;0"],[name=DQCResult_DocumentContent;value="0;0"],[name=DQCResult_DocumentSize;value="0;0"],[name=DQCResult_InvalidFootnotes;value="0;0"],[name=DQCResult_ModifiedMarkers;value="0;0"],[name=DQCResult_ModifiedNumbering;value="0;0"],[name=DQCResult_Objects;value="0;0"],[name=DQCResult_StructureCheck;value="0;0"],[name=DQCStatus;value="Green"],[name=DQCVersion;value="3"],[name=DQCWithWarnings;value="0"],[name=LW_CORRIGENDUM;value="UNUSED"],[name=LW_COVERPAGE_EXISTS;value="True"],[name=LW_COVERPAGE_GUID;value="C84DFD9E-0C97-49DB-9C92-1E00590BE37B"],[name=LW_COVERPAGE_TYPE;value="1"],[name=LW_CROSSREFERENCE;value="UNUSED"],[name=LW_DocType;value="COM"],[name=LW_EMISSION;value="13.1.2025"],[name=LW_EMISSION_ISODATE;value="2025-01-13"],[name=LW_EMISSION_LOCATION;value="BRX"],[name=LW_EMISSION_PREFIX;value="Brussels, "],[name=LW_EMISSION_SUFFIX;value=" "],[name=LW_ID_DOCMODEL;value="SJ-019"],[name=LW_ID_DOCSIGNATURE;value="SJ-019"],[name=LW_ID_DOCSTRUCTURE;value="COM/PL/ORG"],[name=LW_ID_DOCTYPE;value="SJ-019"],[name=LW_ID_STATUT;value="SJ-019"],[name=LW_INSERT_EXP.MOTIFS.NEW;value="1"],[name=LW_INTERETEEE.CP;value="UNUSED"],[name=LW_LANGUE;value="EN"],[name=LW_LEVEL_OF_SENSITIVITY;value="Standard treatment"],[name=LW_NOM.INST;value="EUROPEAN COMMISSION"],[name=LW_NOM.INST_JOINTDOC;value="EMPTY"],[name=LW_PART_NBR;value="1"],[name=LW_PART_NBR_TOTAL;value="1"],[name=LW_REF.II.NEW.CP;value="NLE"],[name=LW_REF.II.NEW.CP_NUMBER;value="0002"],[name=LW_REF.II.NEW.CP_YEAR;value="2025"],[name=LW_REF.INST.NEW;value="COM"],[name=LW_REF.INST.NEW_ADOPTED;value="final"],[name=LW_REF.INST.NEW_TEXT;value="(2025) 6"],[name=LW_REF.INTERNE;value="UNUSED"],[name=LW_SENSITIVITY;value="?xml version="1.0" encoding="utf-8"?SensitivityLevel xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="standard"  nicename EN="Standard treatment" FR="Traitement standard" /  documentPropertyStandard treatment/documentProperty  markingConfig isAvailable="false" isMandatory="false" sensitiveMarkingMandatory="false" specialMarkingMandatory="true" isOptionDisplayInHeaderAvailable="true" sensitiveMarkingListSee="SensitiveMarkings" specialMarkingListSee="SpecialMarkings" sensitiveFootnoteTextSee="sensitiveFootnote" specialFootnoteTextSee="specialFootnote" /  chosenMainMarking xsi:nil="true" /  dateMarking xsi:nil="true" /  releasableToConfig isAvailable="false" institutionListSee="DefaultInstitutions" /  chosenReleasableTo xsi:nil="true" /  detached xsi:nil="true" /  declassify xsi:nil="true" /  headerTexts xsi:nil="true" /  footerTexts xsi:nil="true" /  isRestrictedfalse/isRestricted/SensitivityLevel"],[name=LW_STATUT.CP;value="Proposal for a"],[name=LW_SUPERTITRE;value="UNUSED"],[name=LW_TITRE.OBJ.CP;value="on the position to be taken on behalf of the European Union in the sixty-eighth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971"],[name=LW_TYPE.DOC.CP;value="COUNCIL DECISION"],[name=LwApiVersions;value="LW4CoDe 1.24.5.0; LW 9.0, Build 20240221"]--><p class="Logo">
               <img src="http://publications.europa.eu/resource/image/eclogo.jpg" alt="european flag"/>EUROPEAN COMMISSION</p>
            <p class="Emission">Brussels, 13.1.2025</p>
            <p class="Rfrenceinstitutionnelle">COM(2025) 6 final</p>
            <p class="Rfrenceinterinstitutionnelle">2025/0002(NLE)</p>
            <p class="cpMarking"/>
            <p class="Statut">Proposal for a</p>
            <p class="Typedudocument_cp">COUNCIL DECISION</p>
            <p class="Titreobjet_cp">on the position to be taken on behalf of the European Union in the sixty-eighth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971<br/>
            </p>
            <div class="pageBreak">
               <br/>
            </div>
         </div>
         <div class="content">
            <p id="_GoBack" class="Exposdesmotifstitre">
               <span>EXPLANATORY MEMORANDUM</span>
            </p>
            <p class="li ManualHeading1">
               <span>SUBJECT MATTER OF THE PROPOSAL</span>
            </p>
            <p class="Normal">
               <span>This proposal concerns the decision establishing the position to be taken on behalf of the European Union (EU) in the 68</span><span>th</span><span> session of the United Nations (UN) Commission on Narcotic Drugs (CND) on the scheduling of substances under the UN Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the UN Convention on Psychotropic Substances of 1971. The 68</span><span>th</span><span> session of the CND is scheduled to take place from 10 to 14 March 2025.</span>
            </p>
            <p class="li ManualHeading1">
               <span>CONTEXT OF THE PROPOSAL</span>
            </p>
            <p class="li ManualHeading2">
               <span class="num"><span>1.1.</span></span><span>The </span><span>UN Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the UN Convention on Psychotropic Substances of 1971</span>
            </p>
            <p class="Normal">
               <span>The UN Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, (the 'Convention on Narcotic Drugs')</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref1" href="#footnote1">1</a>
               </span><span> aims to combat drug abuse by coordinated international action. There are two forms of intervention and control that work together. First, it seeks to limit the possession, use, trade in, distribution, import, export, manufacture and production of drugs exclusively to medical and scientific purposes. Second, it combats drug trafficking through international cooperation to deter and discourage drug traffickers.</span>
            </p>
            <p class="Normal">
               <span>The UN Convention on Psychotropic Substances of 1971 (the 'Convention on Psychotropic Substances')</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref2" href="#footnote2">2</a>
               </span><span> establishes an international control system for psychotropic substances. It responded to the diversification and expansion of the spectrum of drugs of abuse and introduced controls over a number of synthetic drugs according to their abuse potential on the one hand and their therapeutic value on the other.</span>
            </p>
            <p class="Normal">
               <span>All the EU Member States are parties to the Conventions, whereas the Union is not. </span>
            </p>
            <p class="Normal">
               <span>The Commission on Narcotic Drugs</span>
            </p>
            <p class="Normal">
               <span>The </span><span>CND is a commission of the UN Economic and Social Council (ECOSOC) and its functions and powers are </span><span>inter alia</span><span> set out in the two Conventions. It is made up of 53 UN Member States elected by the ECOSOC. 13 EU Member States will be members of the CND with the right to vote in March 202</span><span>5</span><span>.</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref3" href="#footnote3">3</a>
               </span><span> </span><span>The Union has an observer status in the CND.</span>
            </p>
            <p class="Normal">
               <span>The envisaged act of the Commission on Narcotic Drugs</span>
            </p>
            <p class="Normal">
               <span>The CND regularly amends the list of substances that are annexed to the Conventions on the basis of recommendations of the World Health Organisation (WHO) which is advised by its Expert Committee on Drug Dependence (ECDD). </span>
            </p>
            <p class="Normal">
               <span>The WHO recommended on </span><span>21 November</span><span> to the UN Secretary General</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref4" href="#footnote4">4</a>
               </span><span> to add</span><span> six</span><span> substances which were critically reviewed by the ECDD to the schedules of the Conventions.</span>
            </p>
            <p class="Normal">
               <span>The CND, in its 68</span><span>th</span><span> session taking place in Vienna 10 to 14 March 2025, is called upon to adopt decisions on the scheduling of these substances under the Conventions. </span>
            </p>
            <p class="Normal">
               <span>Position to be taken on the Union's behalf</span>
            </p>
            <p class="Normal">
               <span>Changes to the schedules of the Conventions have direct repercussions for the scope of application of Union law in the area of drug control for all Member States. Article 1(1) of Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (the ‘Framework Decision’)</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref5" href="#footnote5">5</a>
               </span><span> states that, for the purposes of the Framework Decision, "drug" means a substance covered by either the Convention on Narcotic Drugs or the Convention on Psychotropic Substances and any of the substances listed in the Annex to the Framework Decision. The Framework Decision therefore applies to substances listed in the Schedules to the Convention on Narcotic Drugs and the Convention on Psychotropic Substances. Thus any change to the schedules annexed to these Conventions directly affects common EU rules and alters their scope, in accordance with Article 3(2) of the Treaty on the Functioning of the European Union (TFEU). This is irrespective of whether the substance in question is controlled in the Union.</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref6" href="#footnote6">6</a>
               </span>
            </p>
            <p id="_Hlk178694849 _Hlk178694868" class="Normal">
               <span>The ECDD critically reviewed eight substances at its 47</span><span>th</span><span> meeting, namely one synthetic cannabinoid – hexahydrocannabinol –, four novel synthetic opioids – </span><span>N</span><span>-pyrrolidino protonitazene (protonitazepyne), </span><span>N</span><span>-pyrrolidino metonitazene (metonitazepyne), etonitazepipne (</span><span>N</span><span>-Piperidinyl etonitazene), </span><span>N</span><span>-desethyl-isotonitazene –, one dissociative-type substance – 3-OH-PCP (3-Hydroxy-phencyclidine) –, one cathinone/stimulant – </span><span>N</span><span>-ethylheptedrone – and one medicine – carisoprodol. </span>
            </p>
            <p class="Normal">
               <span>All of the </span><span>eight</span><span> substances are monitored by the European </span><span>Union Drugs Agency</span><span> (EUDA)</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref7" href="#footnote7">7</a>
               </span><span>. Furthermore, </span><span>four</span><span> </span><span>of these substances – </span><span>hexahydrocannabinol, protonitazepyne, metonitazepyne, </span><span>N</span><span>-desethyl-isotonitazene </span><span>– </span><span>are under intensive monitoring by the </span><span>EUDA</span><span>. The ECDD decided to recommend </span><span>six</span><span> </span><span>of these for scheduling: </span><span>protonitazepyne</span><span>, </span><span>metonitazepyne</span><span>, e</span><span>tonitazepipne</span><span>, </span><span>N</span><span>-desethyl-isotonitazene</span><span>, h</span><span>exahydrocannabinol</span><span> and </span><span>carisoprodol</span><span>.</span>
            </p>
            <p class="Normal">
               <span>The Commission proposal for a Union position suggests supporting the WHO recommendations, the control of the above-mentioned six substances, as these are in line with the current state of play of scientific knowledge. As regards these new psychoactive substances, their addition to the Schedules of the Conventions is supported also by information available from the European Database on New Drugs of the EUDA.</span>
            </p>
         </div>
         <div class="content">
            <p class="Normal">
               <span>It is necessary that the Council establishes the Union’s position for the meeting of the CND when it is called to decide on the scheduling of substances. Such position, due to the limitations intrinsic to the observer status of the Union, should be expressed by the Member States that will be members of the CND in March 2025, acting jointly in the interest of the Union within the CND. The Union is not a party to these Conventions but has exclusive competence in this area.</span>
            </p>
            <p class="Normal">
               <span>To this end, the Commission is proposing a Union position to be expressed by the Member States that will be members of the CND in March 202</span><span>5</span><span>, on behalf of the European Union, in the 6</span><span>8</span><span>th</span><span> session of the CND on the scheduling of substances under the Convention on Narcotic Drugs and the Convention on Psychotropic Substances. In the past, the Council adopted such Union positions and thus allowed the EU to speak with one voice at the previous CND meetings regarding the international scheduling, as the Member States participating in the CND voted in favour of the scheduling in line with the adopted Union position</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref8" href="#footnote8">8</a>
               </span><span>.</span>
            </p>
            <p class="li ManualHeading2">
               <span>LEGAL BASIS</span>
            </p>
            <p class="li ManualHeading2">
               <span>Procedural legal basis</span>
            </p>
            <p class="li ManualHeading3">
               <span class="num"><span>1.1.1.</span></span><span>Principles</span>
            </p>
            <p class="Normal">
               <span>Article 218(9) of the TFEU provides for decisions establishing ‘</span><span>the positions to be adopted on the Union’s behalf in a body set up by an agreement, when that body is called upon to adopt acts having legal effects, with the exception of acts supplementing or amending the institutional framework of the agreement</span><span>.’</span>
            </p>
            <p class="Normal">
               <span>Article 218(9) TFEU applies regardless of whether the Union is a member of the body or a party to the agreement</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref9" href="#footnote9">9</a>
               </span><span>.</span>
            </p>
            <p class="Normal">
               <span>The concept of ‘</span><span>acts having legal effects</span><span>’ includes acts that have legal effects by virtue of the rules of international law governing the body in question. It also includes instruments that do not have a binding effect under international law, but that are ‘</span><span>capable of decisively influencing the content of the legislation adopted by the EU legislature</span><span>’</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref10" href="#footnote10">10</a>
               </span><span>.</span>
            </p>
            <p class="li ManualHeading3">
               <span class="num"><span>1.1.2.</span></span><span>Application to the present case</span>
            </p>
            <p class="Normal">
               <span>The CND is "a body set up by an agreement" within the meaning of this Article, given that it is a body established by the United Nations Economic and Social Council (ECOSOC) and that it has been given specific tasks under the Convention on Narcotic Drugs and the Convention on Psychotropic Substances.</span>
            </p>
            <p class="Normal">
               <span>The CND's scheduling decisions are "acts having legal effects'' within the meaning of Article 218(9) TFEU. According to the Convention on Narcotic Drugs and the Convention on Psychotropic Substances, decisions of the CND are binding. If a party submits a CND decision for review to the ECOSOC within the applicable time-limit,</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref11" href="#footnote11">11</a>
               </span><span> the decisions of the ECOSOC on the matter are final. The CND's scheduling decisions also have legal effects in the EU legal order by virtue of Union law, given the fact that they are capable of decisively influencing the content of EU legislation, namely Council Framework Decision 2004/757/JHA. Changes to the schedules of the Conventions have direct repercussions for the scope of application of this EU legal instrument.</span>
            </p>
            <p class="Normal">
               <span>The envisaged act does not supplement or amend the institutional framework of the Agreement.</span>
            </p>
            <p class="Normal">
               <span>Therefore, the procedural legal basis for the proposed decision is Article 218(9) TFEU.</span>
            </p>
            <p class="li ManualHeading2">
               <span class="num"><span>1.2.</span></span><span>Substantive legal basis</span>
            </p>
            <p class="li ManualHeading3">
               <span class="num"><span>1.2.1.</span></span><span>Principles</span>
            </p>
            <p class="Normal">
               <span>The substantive legal basis for a decision under Article 218(9) TFEU depends primarily on the objective and content of the envisaged act in respect of which a position is taken on the Union's behalf.</span>
            </p>
            <p class="li ManualHeading3">
               <span class="num"><span>1.2.2.</span></span><span>Application to the present case</span>
            </p>
            <p class="Normal">
               <span>The main objective and content of the envisaged act relate to illicit drug trafficking. </span>
            </p>
            <p class="Normal">
               <span>Therefore, the substantive legal basis of the proposed decision is Article 83(1) TFEU, which identifies illicit drug trafficking as one of the crimes with a particular cross-border dimension and empowers the European Parliament and the Council to establish minimum rules concerning the definition of offences and sanctions in the area of illicit drug trafficking. </span>
            </p>
            <p class="li ManualHeading2">
               <span class="num"><span>1.3.</span></span><span>Variable geometry</span>
            </p>
         </div>
         <div class="content">
            <p class="Normal">
               <span>Denmark is bound by Council Framework Decision 2004/757/JHA as applicable until 21 November 2018 which states in its Article 1 that “drugs” shall mean any of the substances covered by either the Convention on Narcotic Drugs or the Convention on Psychotropic Substances. Since the CND’s scheduling decisions affect common rules in the area of illicit drug trafficking by which Denmark is bound, Denmark takes part in the adoption of a Council Decision establishing the position to be taken on the Union’s behalf when such scheduling decisions are adopted.</span>
            </p>
            <p class="Normal">
               <span>Ireland is bound by the Framework Decision and is therefore taking part in the adoption of a Council Decision establishing the position to be taken on the Union’s behalf when such scheduling decisions are adopted.</span>
            </p>
            <p class="li ManualHeading2">
               <span class="num"><span>1.4.</span></span><span>Conclusion</span>
            </p>
            <p class="Normal">
               <span>The legal basis of the proposed decision is Article 83(1) TFEU in conjunction with Article 218(9) TFEU.</span>
            </p>
            <p class="li ManualHeading1">
               <span class="num"><span>2.</span></span><span>Budgetary implications</span>
            </p>
            <p class="Normal">
               <span>There are no budgetary implications.</span>
            </p>
            <p class="Rfrenceinterinstitutionnelle">
               <span>2025/0002 (NLE)</span>
            </p>
            <p class="Statut">
               <span>Proposal for a</span>
            </p>
            <p class="Typedudocument">
               <span>COUNCIL DECISION</span>
            </p>
            <p class="Titreobjet">
               <span>on the position to be taken on behalf of the European Union in the sixty-eighth session of the Commission on Narcotic Drugs on the scheduling of substances under the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the Convention on Psychotropic Substances of 1971</span>
               <br/>
            </p>
            <p class="Institutionquiagit">
               <span>THE COUNCIL OF THE EUROPEAN UNION,</span>
            </p>
            <p class="Normal">
               <span>Having regard to the Treaty on the Functioning of the European Union (TFEU), and in particular Article 83(1), in conjunction with Article 218(9) thereof,</span>
            </p>
            <p class="Normal">
               <span>Having regard to the proposal from the European Commission,</span>
            </p>
            <p class="Normal">
               <span>Whereas:</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(1)</span></span><span>The United Nations (UN) Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol ('the Convention on Narcotic Drugs')</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref12" href="#footnote12">12</a>
               </span><span> entered into force on 8 August 1975. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(2)</span></span><span>Pursuant to Article 3 of the Convention on Narcotic Drugs, the Commission on Narcotic Drugs (CND) may decide to add substances to the Schedules of that Convention. It can make changes in the Schedules only in accordance with the recommendations of the World Health Organisation (WHO), but it can also decide not to make the changes recommended by the WHO.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(3)</span></span><span>The UN Convention on Psychotropic Substances of 1971 ('the Convention on Psychotropic Substances')</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref13" href="#footnote13">13</a>
               </span><span> entered into force on 16 August 1976.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(4)</span></span><span>Pursuant to Article 2 of the Convention on Psychotropic Substances, the CND may decide to add substances to the Schedules of that Convention or to remove them, on the basis of recommendations of the WHO. It has broad discretionary powers to take into account economic, social, legal, administrative and other factors, but may not act arbitrarily. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(5)</span></span><span>Changes to the Schedules of </span><span>the Convention on Narcotic Drugs and the Convention on Psychotropic Substances</span><span> have direct repercussions on the scope of application of Union law in the area of drug control. Council Framework Decision 2004/757/JHA</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref14" href="#footnote14">14</a>
               </span><span> applies to substances listed in the Schedules of those Conventions. Thus, any change to the Schedules annexed to those Conventions directly affects common Union rules and alters their scope, in accordance with Article 3(2) of the TFEU.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(6)</span></span><span>The CND</span><span> is to decide</span><span>, during its </span><span>6</span><span>8</span><span>th</span><span> session scheduled fo</span><span>r </span><span>10</span><span> to </span><span>14</span><span> March </span><span>202</span><span>5</span><span> in Vienna, on the </span><span>addition </span><span>of </span><span>six</span><span> new substances</span><span> to the Schedules of the </span><span>Convention on Narcotic Drugs and the Convention on Psychotropic Substances.</span>
            </p>
         </div>
         <div class="content">
            <p class="li ManualConsidrant">
               <span class="num"><span>(7)</span></span><span>The Union is neither a party to the Convention on Narcotic Drugs nor to the Convention on Psychotropic Substances. It has an observer status with no voting rights in the Commission on Narcotic Drugs</span><span>,</span><span> </span><span>of which 13 </span><span>Member States are members with the right to vote in March 202</span><span>5</span><span>.</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref15" href="#footnote15">15</a>
               </span><span> It is necessary for the Council to authorise </span><span>those </span><span>Member States to express the position of the Union on the scheduling of substances under </span><span>those</span><span> Convention</span><span>s</span><span> since decisions on the addition of new substances to the</span><span>ir </span><span>Schedules fall under the exclusive competence of the Union.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(8)</span></span><span>The WHO has recommended the addition of </span><span>four</span><span> new substance</span><span>s</span><span> to Schedule I of the Convention on Narcotic Drugs, three new substances to Schedule II of the Convention on Psychotropic Substances, and one new substance to Schedule IV of the Convention on Psychotropic Substances</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref16" href="#footnote16">16</a>
               </span><span>.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(9)</span></span><span>All substances reviewed by the WHO Expert Committee on Drug Dependence (ECDD) and recommended for scheduling by the WHO are monitored by the </span><span>European Union Drugs Agency</span><span> (</span><span>EUDA</span><span>) as new psychoactive substances under the terms of Regulation </span><span>(EU) 2023/1322</span><span> of the European Parliament and of the Council</span><span class="FootnoteReference">
                  <a class="footnoteRef" id="footnoteref17" href="#footnote17">17</a>
               </span><span>.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(10)</span></span><span>According to the assessment by the ECDD, </span><span>protonitazepyne</span><span> (IUPAC name: </span><span>5-nitro-2-[(4-propoxyphenyl)methyl]-1-(2-pyrrolidin-1-ylethyl)benzimidazole</span><span>)</span><span> is a synthetic opioid in the nitazene analogue family.</span><span> Protonitaz</span><span>e</span><span>pyne has not</span><span> previously</span><span> been formally reviewed by WHO.</span><span> </span><span>Protonitaz</span><span>e</span><span>pyne</span><span> </span><span>has no known therapeutic uses or marketing authorizations</span><span>. </span><span>There is sufficient evidence that protonitazepyne is being or is likely to be abused and may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that protonitazepyne be placed in Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(11)</span></span><span>Protonitazepyne has been detected in </span><span>six</span><span> Member States and is controlled in at least </span><span>two</span><span> Member States. Protonitazepyne is under intensive monitoring by the </span><span>EUDA</span><span>. </span><span>Seventy four acute poisonings with suspected exposure to protonitazepyne were reported by one Member State. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(12)</span></span><span>Therefore, the position </span><span>of the Union should be </span><span>to add protonitazepyne</span><span> </span><span>to </span><span>Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(13)</span></span><span>According to the assessment by the ECDD, metonitazepyne (IUPAC name: 2-[(4-methoxyphenyl)methyl]-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1</span><span>H</span><span>-benzoimidazole) is a synthetic opioid of the nitazene analogue family.</span><span> </span><span>Metonitazepyne</span><span> has not</span><span> previously</span><span> been formally reviewed by WHO. </span><span>Metonitazepyne</span><span> has no known therapeutic uses or marketing authorizations. There is sufficient evidence that </span><span>metonitazepyne</span><span> is being or is likely to be abused and may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that </span><span>metonitazepyne</span><span> be placed in Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(14)</span></span><span>Metonitazepyne </span><span>has been detected in four Member States and is controlled in at least two Member States. Metonitazepyne </span><span>is under intensive monitoring by the EUDA</span><span>. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(15)</span></span><span>Therefore, the position </span><span>of the Union should be </span><span>to add </span><span>metonitazepyne</span><span> </span><span>to Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(16)</span></span><span>According to the assessment by the ECDD,</span><span> </span><span>etonitazepipne</span><span> (</span><span>IUPAC name: </span><span>2-[(4-Ethoxyphenyl)methyl]-5-nitro-1-(2-piperidin-1-ylethyl)-1</span><span>H</span><span>-benzoimidazole</span><span>) </span><span>is one of several synthetic 2-benzylbenzimidazoles opioids, collectively known as “nitazenes”.</span><span> </span><span>Etonitazepipne</span><span> </span><span>has not </span><span>previously </span><span>been formally reviewed by WHO. </span><span>Etonitazepipne</span><span> </span><span>has no known therapeutic uses or marketing authorizations. There is sufficient evidence that </span><span>etonitazepipne</span><span> </span><span>is being or is likely to be abused and may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that </span><span>etonitazepipne</span><span> be placed in Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(17)</span></span><span>Etonitazepipne</span><span> </span><span>has been detected in </span><span>five</span><span> Member States and is controlled in at least </span><span>six</span><span> Member States. </span><span>Etonitazepipne</span><span> </span><span>is under monitoring by the EUDA</span><span>. </span><span>Two deaths and one acute poisoning with confirmed exposure to e</span><span>tonitazepipne</span><span> have been reported by three Member States. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(18)</span></span><span>Therefore, the position </span><span>of the Union should be </span><span>to add </span><span>etonitazepipne</span><span> </span><span>to Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(19)</span></span><span>According to the assessment by the ECDD, </span><span>N</span><span>-desethyl isotonitazene</span><span> (</span><span>IUPAC name: </span><span>N</span><span>-ethyl-2-[2-[(4-isopropoxyphenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamine</span><span>) </span><span>is a benzimidazole-derived synthetic opioid with a chemical structure and pharmacological similarities to drugs under Schedule I of the 1961 United Nations Conventions), such as isotonitazene, and is a metabolite of isotonitazene.</span><span> </span><span>N</span><span>-desethyl isotonitazene has not </span><span>previously </span><span>been formally reviewed by WHO. </span><span>N</span><span>-desethyl isotonitazene has no known therapeutic uses or marketing authorizations. There is sufficient evidence that </span><span>N</span><span>-desethyl isotonitazene is being or is likely to be abused and may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that </span><span>N</span><span>-desethyl isotonitazene be placed in Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(20)</span></span><span>N</span><span>-desethyl isotonitazene</span><span> </span><span>has been detected in </span><span>two</span><span> Member States and is controlled in at least two Member States. </span><span>N</span><span>-desethyl isotonitazene</span><span> </span><span>is under intensive monitoring by the EUDA</span><span>. </span><span>Two deaths with confirmed exposure to </span><span>N</span><span>-desethyl isotonitazene</span><span> have been reported by one Member State. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(21)</span></span><span>Therefore, the position </span><span>of the Union should be </span><span>to add </span><span>N</span><span>-desethyl isotonitazene</span><span> </span><span>to Schedule I of the Convention on Narcotic Drugs.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(22)</span></span><span>According to the assessment by the ECDD, </span><span>hexahydrocannabinol (HHC) (IUPAC name: </span><span>6a,7,8,9,10,10a-hexahydro-6,6,9-trimethyl-3-pentyl-6</span><span>H</span><span>-dibenzo[</span><span>b,d</span><span>]pyran-1-ol</span><span>) </span><span>is a semi-synthetic cannabinoid that is </span><span>most commonly</span><span> synthesized from cannabidiol as a precursor</span><span>. </span><span>Hexahydrocannabinol has not </span><span>previously </span><span>been formally reviewed by WHO</span><span>. </span><span>Hexahydrocannabinol</span><span> </span><span>has no known therapeutic uses or marketing authorizations. There is sufficient evidence that </span><span>hexahydrocannabinol</span><span> is being or is likely to be abused and may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that </span><span>h</span><span>exahydrocannabinol</span><span> be placed in Schedule I</span><span>I</span><span> of the Convention on Psychotropic Substances.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(23)</span></span><span>Hexahydrocannabinol</span><span> has been detected in </span><span>twenty-five</span><span> Member States and is controlled in at least </span><span>twenty</span><span> Member States. </span><span>Hexahydrocannabinol</span><span> is under</span><span> intensive</span><span> monitoring by the</span><span> E</span><span>UDA</span><span>. </span><span>Four cases of acute poisoings with confirmed exposure to hexahydrocannabinol have been reported by two Member States. Seven cases of acute poisoning with probable exposure to hexahydrocannabinol have been reported by two Member States. Six cases of acute poisoning with suspected exposure to hexahydrocannabinol have been reported by three Member States. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(24)</span></span><span>Therefore, the position </span><span>of the Union should be </span><span>to add </span><span>h</span><span>exahydrocannabinol</span><span> to Schedule I</span><span>I</span><span> of the Convention on Psychotropic Substances.</span><span>According to the assessment by the ECDD, </span><span>c</span><span>arisoprodol (</span><span>IUPAC name:  (2RS)-2-[(</span><span>c</span><span>arbamoyloxy)methyl]-2-methylpentyl(1-methylethyl)carbamate</span><span>) is</span><span> a centrally acting muscle relaxant used in the short term as an adjunct to symptomatic treatment of acute musculoskeletal disorders associated with painful muscle spasm</span><span>.</span><span> The potential for misuse of carisoprodol may be related to both its sedative effects and its capacity to enhance the effects of other substances. Thus, the sedative effects of carisoprodol can be potentiated when it is combined with benzodiazepines, opioids or alcohol. Prolonged or excessive use of carisoprodol can lead to dependence. </span><span>Carisoprodol may be diverted from legitimate medical channels and enter the illicit market to be sold without proper medical supervision, increasing potential abuse and adverse consequences. </span><span>Carisoprodol was pre-reviewed in 2001 at the 32</span><span>nd</span><span> ECDD meeting. The Committee did not recommend critical review of carisoprodol at that time. Carisoprodol was further presented, discussed and pre-reviewed in 2023 at the 46</span><span>th</span><span> ECDD meeting, where proceeding to critical review was recommended. Carisoprodol is a prescription medication and appears to be a licensed drug in several countries and territories.</span><span> However, it is no longer used medically in Europe since the European Medicines Agency Committee for Medicinal Products for Human Use suspended all marketing authorizations for carisoprodol throughout Europe.</span><span> Carisoprodol has no known industrial use. </span><span>There is sufficient evidence that </span><span>carisoprodol</span><span> is being or is likely to be abused and may constitute a public health and social problem warranting the placing of the substance under international control. Thus, the WHO recommends that carisoprodol</span><span> </span><span>be placed in Schedule I</span><span>V</span><span> of the Convention on Psychotropic Substances.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(25)</span></span><span>Carisoprodol</span><span> </span><span>has been detected in </span><span>two</span><span> Member States. </span><span>Carisoprodol</span><span> </span><span>is under monitoring by the EUDA. </span><span>Two deaths with confirmed exposure to carisoprodol have been reported by one Member State. </span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(26)</span></span><span>Therefore, the position of the Union should be to add </span><span>c</span><span>arisoprodol</span><span> </span><span>to </span><span>Schedule I</span><span>V</span><span> of the Convention on Psychotropic Substances.</span>
            </p>
         </div>
         <div class="content">
            <p class="li ManualConsidrant">
               <span class="num"><span>(27)</span></span><span>It is appropriate to establish the position to be taken on the Union’s behalf in the CND, as the decisions on scheduling as regards the </span><span>six</span><span> substances</span><span> will be capable of decisively influencing the content of Union law, namely Framework Decision 2004/757/JHA.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(28)</span></span><span>The Union's position is to be expressed by the Member States that are members of the CND, acting jointly.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(29)</span></span><span>Denmark is bound by Framework Decision 2004/757/JHA and is therefore taking part in the adoption and application of this Decision.</span>
            </p>
            <p class="li ManualConsidrant">
               <span class="num"><span>(30)</span></span><span>Ireland is bound by Framework Decision 2004/757/JHA and is therefore taking part in the adoption and application of this Decision,</span>
            </p>
            <p class="Formuledadoption">
               <span>HAS ADOPTED THIS DECISION: </span>
            </p>
            <p class="Titrearticle">
               <span>Article 1</span>
            </p>
            <p class="Normal">
               <span>The position to be taken on the Union's behalf in the sixty-eighth session of the Commission on Narcotic Drugs, from 10 to 14 March 2025, when that body is called upon to adopt decisions on the addition of substances to the Schedules of the United Nations Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, and the United Nations Convention on Psychotropic Substances of 1971, is set out in the Annex to this Decision.</span>
            </p>
            <p id="_Hlk126129799" class="Titrearticle">
               <span>Article 2 </span>
            </p>
            <p class="Normal">
               <span>The position referred to in Article 1 shall be expressed by the Member States that are members of the Commission on Narcotic Drugs, acting jointly in the interest of the Union.</span>
            </p>
            <p class="Titrearticle">
               <span>Article 3</span><span> </span>
            </p>
            <p class="Normal">
               <span>This Decision is addressed to the Member States.</span>
            </p>
            <p class="Fait">
               <span>Done at Brussels,</span>
            </p>
            <div class="signature">
               <p class="Institutionquisigne">
                  <span><span class="tab">   </span>For the Council</span>
               </p>
               <p class="Personnequisigne">
                  <span><span class="tab">   </span>The President</span>
               </p>
            </div>
         </div>
         <div class="content">
            <dl id="footnotes">
               <dd id="footnote1">
                  <span class="num">
                     <a class="footnote" href="#footnoteref1">(1)</a>
                  </span><span>
                     <span class="tab">   </span>United Nations Treaty Series, vol. 978, No. 14152.</span>
               </dd>
               <dd id="footnote2">
                  <span class="num">
                     <a class="footnote" href="#footnoteref2">(2)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>United Nations Treaty Series, vol. 1019, No. 14956.</span>
               </dd>
               <dd id="footnote3">
                  <span class="num">
                     <a class="footnote" href="#footnoteref3">(3)</a>
                  </span><span>
                     <span class="tab">   </span>Austria, Belgium, France, Finland, Hungary, Italy, Lithuania, Malta, Netherlands, Poland, Portugal, Slovenia, and Spain.</span>
               </dd>
               <dd id="footnote4">
                  <span class="num">
                     <a class="footnote" href="#footnoteref4">(4)</a>
                  </span><span>
                     <span class="tab">   </span></span>
                  <a class="externalRef"
                     href="https://www.who.int/groups/ecdd/forty-seventh-ecdd-documents">https://www.who.int/groups/ecdd/forty-seventh-ecdd-documents</a>
                  <span> </span>
               </dd>
               <dd id="footnote5">
                  <span class="num">
                     <a class="footnote" href="#footnoteref5">(5)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>Directive (EU) 2017/2103 of The European Parliament and of The Council of 15 November 2017 amending Council Framework Decision 2004/757/JHA in order to include new psychoactive substances in the definition of ‘drug’ and repealing Council Decision 2005/387/JHA, OJ L 305, 21.11.2017, s. 12</span><span>. </span>
               </dd>
               <dd id="footnote6">
                  <span class="num">
                     <a class="footnote" href="#footnoteref6">(6)</a>
                  </span><span>
                     <span class="tab">   </span>See the Annex to the Framework Decision.</span>
               </dd>
               <dd id="footnote7">
                  <span class="num">
                     <a class="footnote" href="#footnoteref7">(7)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006</span><span>, </span><span>OJ L 166, 30.6.2023, p. 6–47</span><span>.</span><span> </span>
               </dd>
               <dd id="footnote8">
                  <span class="num">
                     <a class="footnote" href="#footnoteref8">(8)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>With one single exception which has been referred to the Court of Justice.</span>
               </dd>
               <dd id="footnote9">
                  <span class="num">
                     <a class="footnote" href="#footnoteref9">(9)</a>
                  </span><span>
                     <span class="tab">   </span>Judgment of the Court of Justice of 7 October 2014, Germany v Council, C-399/12, ECLI:EU:C:2014:2258, paragraph 64. </span>
               </dd>
               <dd id="footnote10">
                  <span class="num">
                     <a class="footnote" href="#footnoteref10">(10)</a>
                  </span><span>
                     <span class="tab">   </span>Judgment of the Court of Justice of 7 October 2014, Germany v Council, C-399/12, ECLI:EU:C:2014:2258, paragraphs 61</span><span> </span><span>to 64. </span>
               </dd>
               <dd id="footnote11">
                  <span class="num">
                     <a class="footnote" href="#footnoteref11">(11)</a>
                  </span><span>
                     <span class="tab">   </span>Article 3(8) of the Convention on Narcotic Drugs; Article 2(7) of the Convention on Psychotropic Substances.</span>
               </dd>
               <dd id="footnote12">
                  <span class="num">
                     <a class="footnote" href="#footnoteref12">(12)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>United Nations Treaty Series, vol. 978, No. 14152.</span>
               </dd>
               <dd id="footnote13">
                  <span class="num">
                     <a class="footnote" href="#footnoteref13">(13)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>United Nations Treaty Series, vol. 1019, No. 14956.</span>
               </dd>
               <dd id="footnote14">
                  <span class="num">
                     <a class="footnote" href="#footnoteref14">(14)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (</span><span>OJ L 335, 11.11.2004, p. 8).</span>
               </dd>
               <dd id="footnote15">
                  <span class="num">
                     <a class="footnote" href="#footnoteref15">(15)</a>
                  </span><span>
                     <span class="tab">   </span>Austria, Belgium, France, Finland, Hungary, Italy, Lithuania, Malta, Netherlands, Poland, Portugal, Slovenia, and Spain.</span>
               </dd>
               <dd id="footnote16">
                  <span class="num">
                     <a class="footnote" href="#footnoteref16">(16)</a>
                  </span><span>
                     <span class="tab">   </span></span>
                  <a class="externalRef"
                     href="https://www.who.int/groups/ecdd/forty-seventh-ecdd-documents">https://www.who.int/groups/ecdd/forty-seventh-ecdd-documents</a>
                  <span> </span><span>
                     <span class="tab">   </span></span>
               </dd>
               <dd id="footnote17">
                  <span class="num">
                     <a class="footnote" href="#footnoteref17">(17)</a>
                  </span><span>
                     <span class="tab">   </span></span><span>Regulation (EU) 2023/1322 of the European Parliament and of the Council of 27 June 2023 on the European Union Drugs Agency (EUDA) and repealing Regulation (EC) No 1920/2006</span><span>, </span><span>OJ L 166, 30.6.2023, p. 6–47</span><span>.</span><span> </span>
               </dd>
            </dl>
         </div>
      </div>
   </body>
</html>
